We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanoparticle-Augmented Spectroscopy Reveals Structure of Alzheimer's Disease Peptide

By LabMedica International staff writers
Posted on 06 Sep 2015
The use of lipid bilayer-encapsulated silver nanoparticles to increase the sensitivity of a Raman spectroscopy technique allowed researchers to determine the structure of Alzheimer's disease-related membrane-attached oligomers of amyloid-beta40 (Abeta40) peptide.

Raman spectroscopy exploits the inelastic scattering (so-called “Raman” scattering) phenomena to detect spectral signatures of important disease progression biomarkers, including lipids, proteins, and amino acids. More...
In a novel modification of the Raman technique, investigators at the Tata Institute of Fundamental Research (Mumbai, India) and the University of Toronto (Canada) introduced a surface enhanced Raman spectroscopy technique that could determine the conformation of membrane-bound proteins, at low micromolar concentrations, and also in the presence of a substantial membrane-free fraction. Unlike conventional surface enhanced Raman spectroscopy, this approach did not require immobilization of molecules, as it used spontaneous binding of proteins to lipid bilayer-encapsulated silver nanoparticles.

The investigators applied this technique to probe the structure of membrane-attached oligomers of amyloid-beta40 (Abeta40), whose conformation is needed to explain certain aspects of Alzheimer’s disease.

They reported in the August 25, 2015, online edition of the journal ACS Nano that isotope-shifts in the Raman spectra helped them to obtain secondary structure information at the level of individual residues. Results showed the presence of a beta-turn, flanked by two beta-sheet regions. The investigators then used solid-state NMR data to confirm the presence of the beta-sheets in these regions. In the membrane-attached oligomer, they found a strongly contrasting and near-orthogonal orientation of the backbone H-bonds compared to what is found in the mature, less-toxic Abeta fibrils.

Contributing author Dr. Gilbert Walker, professor of chemistry at the University of Toronto, said, "While the amyloid beta got fooled by the fat layer-encased silver nanoparticles that mimicked the outer membranes of living cells and stuck to the membrane, the silver inside enhanced the signal to a measurable level and acted as a light beacon to reveal the peptide signature."

"Everybody wants to make the key to solve Alzheimer's disease, but we do not know what the lock looks like. We now have a glimpse of something which could be the lock. May be it is still not the real thing, but as of now, this is our best bet," said senior author Dr. Sudipta Maiti, professor of chemical sciences at the Tata Institute of Fundamental Research.

Related Links:

Tata Institute of Fundamental Research
University of Toronto



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.